GoAI
Get started
Damora Therapeutics, Inc. logo

Damora Therapeutics, Inc.

DMRA

NASDAQHealthcareBiotechnology

Open in GoAI

Regular session

$30.95

+$0.13 · +0.42%

Aug 24, 12:29 PM ET

DMRA company overview

Regular session · ET · Market data may be delayed.

Company profile

Industry
Biotechnology
Sector
Healthcare
Headquarters
US

Market position

Day range

Current $30.95

52-week range

Current $30.95

Open
$30.75
Previous close
$30.82
Volume
142.39K
Market cap
1.91B USD
50-day average
$28.1097
+10.10% above average
200-day average
$25.4075
+21.81% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
-226.19M USD
P/E (TTM)
-0.25×
P/B (TTM)
3.67×
P/S (TTM)
0×
EV / EBITDA
1.08×
Earnings yield
-669.07%
Free cash flow yield
-21.45%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
-87.29%
Return on assets
-80.54%
Return on invested capital
-87.69%

Financial health

Debt / equity
0×
Current ratio
12.98×
Altman Z-score
39.39
Piotroski F-score
3 of 9

Financial statements

Income trends

Operating income

−210.87M USD-1147.98%

Net income

−209.84M USD-878.77%
Income trends across reported periods2.5M USD−75.09M USD−152.68M USD−230.27M USDOperating income, FY2021: −52.23M USDOperating income, FY2022: −61.21M USDOperating income, FY2023: −36.46M USDOperating income, FY2024: −16.9M USDOperating income, FY2025: −210.87M USDNet income, FY2021: −51.75M USDNet income, FY2022: −61.62M USDNet income, FY2023: −38.35M USDNet income, FY2024: −21.44M USDNet income, FY2025: −209.84M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −52.23M USD. Operating income FY2022 −61.21M USD. Operating income FY2023 −36.46M USD. Operating income FY2024 −16.9M USD. Operating income FY2025 −210.87M USD. Net income FY2021 −51.75M USD. Net income FY2022 −61.62M USD. Net income FY2023 −38.35M USD. Net income FY2024 −21.44M USD. Net income FY2025 −209.84M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Cost of goods sold—181K USD830K USD490K USD441K USD
Gross profit—−181K USD−830K USD−490K USD−441K USD
Research and development201.19M USD6.4M USD23.77M USD48.21M USD38.49M USD
Selling, general, and administrative9.69M USD10.32M USD11.86M USD12.51M USD13.3M USD
Operating expenses210.87M USD16.72M USD35.63M USD60.72M USD51.79M USD
Interest income1.17M USD844K USD1.69M USD722K USD156K USD
Depreciation and amortization34K USD181K USD830K USD490K USD441K USD
Operating income−210.87M USD−16.9M USD−36.46M USD−61.21M USD−52.23M USD
Net income−209.84M USD−21.44M USD−38.35M USD−61.62M USD−51.75M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
56%
5 beats, 4 misses, 0 met estimates
Average EPS surprise
-523.32%
9 comparable reports
Latest EPS result
-0.39
Estimate -0.41 · Beat by 5.79%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.08-1.93-3.78-5.63Q1 '25MissQ2 '25No estimateQ3 '25No estimateQ4 '25MissQ1 '26MissQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 19, 2025: actual -5.22, estimate -2.97, surprise -75.76%, Miss. Q2 2025, reported May 8, 2025: actual -1.92, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 5, 2025: actual -2.6, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Nov 6, 2025: actual -2.36, estimate -0.097, surprise -2337.76%, Miss. Q1 2026, reported Mar 18, 2026: actual -3.24, estimate -0.14, surprise -2216.35%, Miss. Q2 2026, reported May 12, 2026: actual -0.62, estimate -0.21, surprise -195.24%, Miss. Q3 2026, reported Aug 11, 2026: actual -0.39, estimate -0.414, surprise +5.79%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate -0.44, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$43.75

41.36% upside
Past 12 months12-month forecastHigh $50.00Average $43.75Low $40.00

Rating distribution

3 ratings

Limited analyst sample: 3 ratings. Interpret the distribution with caution.

Strong buy00%
Buy3100%
Hold00%
Sell00%
Strong sell00%

Recent analyst actions

3 institutions
HC Wainwright & Co.maintainBuy

DMRA peers

Amgen Inc. logo

AMGN

Amgen Inc.

$441.01

+0.38%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.17

+0.03%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$547.77

-0.05%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$376.6

-0.58%

Sanofi logo

SNY

Sanofi

$45.602

-0.54%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$825.38

-1.04%

ETFs holding DMRA

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
41.2M
Weight
0.05%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$298.35-0.54%
State Street SPDR S&P Biotech ETF logoState Street SPDR S&P Biotech ETFXBI
Market value
22.8M
Weight
0.20%
AUM
11.39B USD
Expense ratio
0.35%
Price / 1D
$164.08-1.00%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
10.44M
Weight
0.07%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$384.03-0.86%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
8.69M
Weight
0.05%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$120.62-0.52%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
6.17M
Weight
0.01%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$243.69-0.75%
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
4.72M
Weight
0.03%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.24-0.26%
Vanguard Russell 2000 Growth ETF logoVanguard Russell 2000 Growth ETFVTWG
Market value
1.15M
Weight
0.07%
AUM
1.7B USD
Expense ratio
0.06%
Price / 1D
$280.46-0.80%
Fidelity Fundamental Small-Mid Cap ETF logoFidelity Fundamental Small-Mid Cap ETFFFSM
Market value
921.85K
Weight
0.07%
AUM
1.5B USD
Expense ratio
0.43%
Price / 1D
$37.05-0.70%

Continue in GoAI

Research DMRA

research.disclaimer